scispace - formally typeset
Open AccessJournal ArticleDOI

A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models

Reads0
Chats0
TLDR
Serially passaged xenografts show biologic consistency with the tumor of origin, are phenotypically stable across multiple transplant generations at the histologic, transcriptomic, proteomic, and genomic levels, and show comparable treatment responses as those observed clinically.
Abstract
Breast cancer research is hampered by difficulties in obtaining and studying primary human breast tissue, and by the lack of in vivo preclinical models that reflect patient tumor biology accurately. To overcome these limitations, we propagated a cohort of human breast tumors grown in the epithelium-free mammary fat pad of severe combined immunodeficient (SCID)/Beige and nonobese diabetic (NOD)/SCID/IL-2γ-receptor null (NSG) mice under a series of transplant conditions. Both models yielded stably transplantable xenografts at comparably high rates (∼21% and ∼19%, respectively). Of the conditions tested, xenograft take rate was highest in the presence of a low-dose estradiol pellet. Overall, 32 stably transplantable xenograft lines were established, representing 25 unique patients. Most tumors yielding xenografts were “triple-negative” [estrogen receptor (ER)−progesterone receptor (PR)−HER2+; n = 19]. However, we established lines from 3 ER−PR−HER2+ tumors, one ER+PR−HER2−, one ER+PR+HER2−, and one “triple-positive” (ER+PR+HER2+) tumor. Serially passaged xenografts show biologic consistency with the tumor of origin, are phenotypically stable across multiple transplant generations at the histologic, transcriptomic, proteomic, and genomic levels, and show comparable treatment responses as those observed clinically. Xenografts representing 12 patients, including 2 ER+ lines, showed metastasis to the mouse lung. These models thus serve as a renewable, quality-controlled tissue resource for preclinical studies investigating treatment response and metastasis. Cancer Res; 73(15); 4885–97. ©2013 AACR .

read more

Citations
More filters
Journal ArticleDOI

Breast cancer brain metastasis: insight into molecular mechanisms and therapeutic strategies

TL;DR: In this paper, the authors outline progress surrounding the molecular mechanisms involved in breast cancer brain metastasis as well as experimental methods and research models to better understand the process and provide an overview of current therapies and highlighting innovative research towards developing novel efficacious targeted therapies.
Journal ArticleDOI

Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine.

TL;DR: Patient-derived xenograft (PDX) tumor models represent a valuable platform for identifying new biomarkers and novel targets, to evaluate therapy response and resistance mechanisms and demonstrate that PDX models provide a multitude of possibilities to identify and validate biomarkers, signaling pathways and resistance mechanism for clinically relevant improvement in cancer therapy.
Journal ArticleDOI

Bioengineering Models for Breast Cancer Research.

TL;DR: Recent advances in the use of three-dimensional cell culture models to study various aspects of BC disease in vitro are described and the emerging area of studying BC dormancy using these models is reviewed.
Journal ArticleDOI

Advances in Precision Medicine: Tailoring Individualized Therapies.

TL;DR: Advances in precision medicine presented at the Irish Association for Cancer Research Annual Meeting are discussed, highlighting examples where personalized medicine approaches have led to precision discovery in individual tumors, informing customized treatment programs.
Journal ArticleDOI

Image-guided photo-therapeutic nanoporphyrin synergized HSP90 inhibitor in patient-derived xenograft bladder cancer model.

TL;DR: A novel multifunctional nanoporphyrin platform loaded with an HSP90 inhibitor 17AAG (NP-AAG) for use as a multi-modality therapy against bladder cancer was evaluated and could dramatically improve management for bladder cancers with minimal toxicity.
References
More filters
Journal ArticleDOI

Prospective identification of tumorigenic breast cancer cells

TL;DR: The ability to prospectively identify tumorigenic cancer cells will facilitate the elucidation of pathways that regulate their growth and survival and strategies designed to target this population may lead to more effective therapies.
Journal ArticleDOI

Mesenchymal stem cells within tumour stroma promote breast cancer metastasis

TL;DR: It is demonstrated that bone-marrow-derived human mesenchymal stem cells, when mixed with otherwise weakly metastatic human breast carcinoma cells, cause the cancer cells to increase their metastatic potency greatly when this cell mixture is introduced into a subcutaneous site and allowed to form a tumour xenograft.
Journal ArticleDOI

Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer

TL;DR: It is confirmed that a prognostically relevant differentiation hierarchy exists across all breast cancers in which the claudin-low subtype most closely resembles the mammary epithelial stem cell.
Related Papers (5)